NeuShen Therapeutics has closed an $80.0M Series B round, a significant infusion for a biotech focused on psychiatric and neurological disorders. The company is developing new therapies aimed at conditions that affect millions of patients, though it has not disclosed which investors participated in the round.
The capital arrives as the field faces mounting pressure to move beyond existing treatment options, which often carry limited efficacy or burdensome side effects. NeuShen’s stated mission is to address that gap with novel approaches, and this funding will support its pipeline as it advances toward clinical milestones.
.png&w=3840&q=75)
